Introduction {#S0001}
============

Delirium is an acute reversible neurocognitive disorder status, manifesting as disturbance of consciousness, attention deficit, change in cognitive ability, and disturbed sleep cycle.[@CIT0001] The incidence of delirium in society is about 1--2%.[@CIT0002],[@CIT0003] Postoperative delirium (POD) is a delirium state arising after surgery. The incidence of POD differs due to surgical type and risk, with fluctuation between 12%-51%.[@CIT0004] The reports on the incidence of LT POD are substantially different in the literature. The incidence of LT POD has been reported to be 10.0%-26.7%,[@CIT0005],[@CIT0007] but Wang et al reported an incidence of up to 47.4%.[@CIT0008]

There are few studies on the risk factors of LT POD. Previous studies have shown that a history of alcohol abuse, hepatic encephalopathy, acute physiology and chronic health evaluation II (APACHE) score ≥16, Child-Pugh level C, Model for End-Stage Liver Disease (MELD) score ≥15, preoperative hemodialysis, and liver donor type are related with the occurrence of LT POD.[@CIT0006],[@CIT0008] LT POD increases medical cost, prolongs the duration of mechanical ventilation, ICU length of stay, hospital length of stay, increases the incidence of other complications, and short-term and long-term mortality.[@CIT0005],[@CIT0007]

This retrospective study analyzed the clinical information of 159 LT patients from August 2018 to May 2019 in the Second Xiangya Hospital, Central South University, to confirm the incidence and identify relevant risk factors of LT POD.

Patients and Methods {#S0002}
====================

Patients {#S0002-S2001}
--------

LT patients in the Second Xiangya Hospital, Central South University from Aug. 2018 to May 2019 were enrolled. Inclusion criteria included: (1) age ≥18 years old, (2) liver donor after brain death, (3) whole orthotopic liver transplantation. Exclusion criteria included: (1) multi-organ transplantation, (2) postoperative diagnosis of organic brain lesions, (3) primary liver graft malfunction, (4) congenital or genetic diseases, (5) a Richmond agitation sedation scale (RASS) ≤ −4.

We guarantee that there were not organs of prisoners, coerced, or paid individuals used in this study. We confirm all organs were from voluntary donation with written informed consent. This study was reviewed and approved by the Ethics Committee of the Second Xiang-ya Hospital. They were conducted in accordance with the Declaration of Istanbul (in addition to the Declaration of Helsinki).

Study Methods {#S0002-S2002}
-------------

We collected the following variables from the clinical records: sex, age, weight, previous medical history (ie, diabetes, hypertension, history of abdominal surgery, history of neuropsychosis), smoking history, alcohol abuse history, emergency surgery (preoperative hospitalization ≤3d), preoperative diagnosis (eg, liver cancer, acute liver failure, pre-transplant hepatic encephalopathy), liver function staging (Child-Pugh staging, MELD score), laboratory results for 3 days preoperatively (hepatic and renal function, electrolytes, coagulation function, blood ammonia and lactic acid). We also collected intraoperative information: time of operation, anhepatic period, intraoperative blood transfusion (eg, red blood cell, plasma, cryoprecipitate), intraoperative lactic acid, hypotension measured as systolic pressure \<30% of baseline value, surgical procedure (eg, classic, piggyback). Postoperative information included: laboratory results on day one postoperatively (hepatic and renal function, electrolytes, coagulation function, blood ammonia and lactic acid), intubation duration, ICU length of stay, delirium duration, and postoperative hospital length of stay. We also collected information on the donor: age, liver weight, cold ischemia time, liver function on either the day before or day of harvest, electrolyte, donor liver pathological before infusion.

Two doctors independently diagnosed POD using the CAM-ICU scale. In there was no agreement, a third doctor made the diagnosis. Patients were assigned to either the POD or non-POD group (control group) to analyze the clinical information.

In our center, we used livers that were donated after brain death and obtained by in situ cold perfusions with liver and kidney together. The surgical procedure was either classic liver transplantation or modified piggyback liver transplantation with or without ligation of the splenic artery. After surgery, the patients were transferred into ICU with tracheal intubation. Basiliximab 20 mg was administered at 2 hours preoperatively and 4 days postoperatively. Methylprednisolone 500 mg was administered during the anhepatic period. Tacrolimus and mycophenolate mofetil were used for anti-rejection at 3 days postoperatively to maintain the concentration of tacrolimus at 8--12 ng/mL.

Statistical Analysis {#S0002-S2003}
--------------------

SPSS 24.0 software was used to analyze the data. P\<0.05 was defined as statistical significance. Normally distributed data were expressed as mean ± SD and analyzed by two-sample *t*-test. Non-normal measurement data were expressed as medians (Q25, Q75), and analyzed with the Mann--Whitney *U*-test. Dichotomous data were analyzed with a chi-square test. The univariate factors with a P\<0.1 were included in the binary logistic regression analysis.

Results {#S0003}
=======

General Information {#S0003-S2001}
-------------------

A total of 159 patients were enrolled ([Figure 1](#F0001){ref-type="fig"}). Forty-two were diagnosed with a POD (26.4%) with an average age of 47.38 ± 9.29 years. Our sample included 33 men and nine women ([Table 1](#T0001){ref-type="table"}). A total of 117 patients were classified as non-POD (a control group), including 101 men and 16 women. The average age of the control group was 49.19 ± 8.98 years ([Table 1](#T0001){ref-type="table"}).Table 1Patients' CharacteristicsVariablePOD Group (n=42)Non-POD Group (n=117)PAge (Y)47.38±9.2949.19±8.980.279Male33 (78.6%)101 (86.3%)0.236Preoperative diabetes6 (14.3%)17 (14.5%)0.969Preoperative pulmonary infection14 (33.3%)23 (19.7%)0.072Preoperative hypertension1 (2.4%)8 (6.8%)0.495Smoking history18 (42.9%)43 (36.8%)0.485Drinking history17 (40.5%)38 (32.5%)0.360Abdominal surgery history11 (26.2%)19 (16.2%)0.157Neuropsychosis history2 (4.8%)3 (2.6%)0.853Emergency operation19 (45.2%)52 (44.4%)0.925[^1] Figure 1Flow chart of patients with LT.

Comparison of Clinical Information Between POD and Non-POD Groups {#S0003-S2002}
-----------------------------------------------------------------

There was no statistical difference found with patient characteristics, such as age and sex (P\>0.05) ([Table 1](#T0001){ref-type="table"}). We analyzed the preoperative information and found the following variables were statistically elevated in the POD group: acute hepatic failure, hepatic encephalopathy, Child-Pugh level C, MELD score ≥15, white blood cells (WBC), percentage of neutrophils (N%), total bilirubin (TBIL), direct bilirubin (DBIL), international normalized ratio (INR), plasma fibrinogen (FIB), and ammonia. Liver cancer in the POD group was significantly lower than in controls ([Table 2](#T0002){ref-type="table"}). Among the intraoperative variables, the following, time of operation, anhepatic period, intraoperative red blood cells and cryoprecipitate, lactic acid, and hypotension, were significant. These variables were significantly higher in the POD group compared to the non-POD group (P\<0.05) ([Table 3](#T0003){ref-type="table"}). Postoperative measurements of alanine aminotransferase (ALT), aspartate aminotransferase (AST), TBIL, DBIL, INR, and FIB in the POD group were all significantly higher than those in the non-POD group (P\<0.05) ([Table 3](#T0003){ref-type="table"}). Donor characteristics (eg, age, sex) were not significantly different between POD and controls ([Table 4](#T0004){ref-type="table"}).Table 2Preoperative Information of LT PatientsVariablePOD Group (n=42)Non-POD Group (n=117)PLiver cancer4 (9.5%)41 (35.0%)0.002Acute hepatic failure19 (45.2%)22 (18.8%)0.001Liver cirrhosis36 (85.7%)96 (82.1%)0.588 Hepatitis B28 (66.7%)84 (71.8%)0.532 Hepatitis C3 (7.1%)4 (3.4)0.568 Alcoholic7 (16.7%)14 (11.0%)0.337 Biliary3 (7.1%)8 (6.8%)1.000Autoimmunity3 (7.1%)2 (1.7%)0.224 Other2 (4.8%)5 (2.6%)0.868 Hepatic encephalopathy21 (50.0%)13 (11.1%)\<0.001Child-pugh\
 ≥9\
 \<912 (10,13)\
38 (90.5%)\
4 (9.5%)9 (8,11)\
75 (64.1%)\
59 (35.9%)\<0.001\
0.001MELD\
 ≥25\
 15--24\
 \<1525 (15,33)\
21(50.0%)\
11(26.2%)\
10(23.8%)12 (6,22)\
21(17.9%)\
27(23.1%)\
69(59.0%)\<0.001\
\<0.001WBC (10^9^/L)6.94 (4.09,12.00)4.64 (3.08,6.39)0.002N%78.15 (67.15,86.18)70.30 (63.85,78.25)0.003HGB (g/L)96.50 (75.75,114.00)102.00 (85.00,124.00)0.129Na (mmol/L)138.10 (132.70,141.45)137.70 (135.20,139.80)0.635Mg (mmol/L)0.83 (0.76,0.93)0.81 (0.75,0.87)0.264CREA (μmol/l)69.10 (52.20,111.70)66.7 (54.6,89.6)0.411Creatinine clearance rate101.49 (73.49,139.59)103.24 (80.34,133.89)0.708PAB (mg/L)79.45 (47.18,94.00)85.4 (50.05,107.90)0.170ALB (g/L)34.45 (29.85,37.50)33.3 (29.65--36.3)0.250TBIL (μmol/L)291.95 (217.85,429.75)51.2 (23.9,300.1)\<0.001DBIL (μmol/L)165.35 (97.85,293.70)32.5 (12.3,199.3)\<0.001INR2.55 (1.69,3.42)1.54 (1.25,2.08)\<0.001FIB (g/L)1.43 (1.06,1.80)1.60 (1.10,2.41)0.043Ammonia (μmol/L)\
 ≥46\
 \<4646.65 (32.33,69.63)\
22 (52.4%)\
20 (47.6%)33.3 (27.85,41.5)\
17 (14.5%)\
100 (85.5%)\<0.001\
\<0.001[^2] Table 3Intraoperative and Postoperative Information of LT PatientsVariablePOD Group (n=42)Non-POD Group (n=117)PTime of operation (min)510.00 (423.75,569.50)429.00 (390.00,487.50)\<0.001Anhepatic period (min)75.00 (62.00,84.00)65.00 (56.00,72.50)0.001Red blood cell (u)8.75 (4.38,15.50)6.00 (3.00,10.25)0.01Frozen plasma (mL)1450 (1150,1825)1250 (925,1650)0.19Cryoprecipitate (u)30.00 (20.00,39.50)20.00 (10.75,36.75)0.006Lactic acid (mmol/l)4.50 (3.38,7.15)3.80 (2.55,5.10)0.008Classic LT35 (83.3%)93 (79.5%)0.589Ligation of the splenic artery7 (16.7%)25 (21.4%)0.515ALT (u/l)744.35 (399.68,1029.20)473.10 (262.15,779.40)0.012AST (u/l)1237.40 (720.98,2573.50)867.50 (408.65,1415.80)0.003TBIL (μmol/l)148.15 (101.83,223.33)96.00 (55.05,157.80)\<0.001DBIL (μmol/l)108.45 (71.33,155.10)65.70 (35.45,124.55)0.001ALB (g/l)36.45 (32.60,40.86)37.50 (35.40,40.90)0.318PAB (mg/l)110.90 (94.30,127.68)106.50 (92.20,127.50)0.777CREA (μmol/l)90.75 (75.63,166.10)83.50 (109.90,67.05)0.067Creatinine clearance rate86.86 (48.43,99.52)82.25 (64.39,102.800.321INR1.67 (1.44,2.01)1.53 (1.35,1.77)0.024FIB (g/l)2.00 (1.45,2.50)2.24 (1.80,2.68)0.021Ammonia (μmol/l)34.60 (28.83,42.60)37.30 (31.05,43.650.247Lactic acid (mmol/l)2.17 (1.46,2.96)2.34 (1.57,3.06)0.387[^3] Table 4Information of Donated LiverVariablePOD Group (n=42)Non-POD Group (n=117)PAge of donor (Y)46 (37,56)48 (39,55)0.547Liver weight (g)1310 (1165,1475)1340 (1155,1560)0.879Cold ischemia time (min)506.00 (433.75,550.00)470.00 (415.00,523.00)0.105ALT (u/l)32.50 (22.20,51.70)31.50 (20.27,58.05)0.780AST (u/l)42 (24.95,73.15)48.55 (29.00,90.12)0.426TBIL (μmol/l)13.65 (8.86,24.65)13.00 (9.50,19.86)0.588ALB (g/l)36.30 (30.96,42.53)35.58 (31.16,40.52)0.547Na (mmol/l)150.70 (140.00,162.45)146.00 (139.00,155.00)0.150PT (sec)12.50 (11.40,14.55)12.40 (10.90,14.00)0.584INR1.01 (0.96,1.24)1.04 (0.92,1.20)0.996FIB (g/l)3.15 (2.55,4.11)3.20 (2.20,4.86)0.949Fatty liver7 (16.7%)27 (23.1%)0.385[^4]

Risk Factor of POD in LT Patients {#S0003-S2003}
---------------------------------

We defined POD occurrence as the dependent variable of interest. Independent variables were selected from the univariate tests when the criteria of P\<0.1 were met. Findings from the logistic regression were: preoperative ammonia (≥46 vs.\<46 μmol/L; OR 3.51, 95% CI \[1.31--9.46\], *P*\<0.05), MELD score (≥15 vs.\<15; OR 3.33, 95% CI \[1.27--8.79\], P\<0.05), presence of hepatic encephalopathy (OR 3.30, 95% CI \[1.20--9.07\], P\<0.05), AST on day one postoperatively (OR 1.33, 95% CI \[1.06 −1.68\], P\<0.05), anhepatic period (OR 1.04, 95% CI \[1.02 −1.06\], P\<0.01). There was no collinearity among those five factors, and the test of goodness for fit for the equation was 84.3% ([Table 5](#T0005){ref-type="table"}).Table 5Multivariate Logistic Regression Analysis of Risk of Postoperative Delirium After Liver TransplantationVariableOR After Correction95% CIPHepatic encephalopathy3.2981.200--9.0650.021Preoperative blood ammonia (≥46)3.5131.306--9.4550.013MELD (≥15)3.3341.265--8.7860.015Postoperative AST1.3301.055--1.6770.016Anhepatic period1.0391.015--1.0640.001

Influence of Delirium {#S0003-S2004}
---------------------

Of the patients diagnosed with POD, 78.6% (33/42) showed delirium 3 days postoperatively. The median duration was 5 (3--7) days. Intubation time, ICU length of stay, and medical cost in the POD group were more than those in the non-POD group, but no statistical difference was found in postoperative hospital length of stay ([Table 6](#T0006){ref-type="table"}).Table 6Influence of LT PODVariablePOD Group (n=42)Non-POD Group (n=117)PPOD Onset (day)2(1,3)\--POD Duration (day)5(3,7)\--Intubation time (min)2925.0 (1857.5,5257.5)1410.0 (1053.0--1727.0)\<0.001ICU length of stay (d)6 (4,8)4 (3,4)\<0.001Postoperative hospital length of stay (d)28.0 (22.5,40.0)26.0 (22.0,34.5)0.378Medical cost (ten thousand yuan)43.96(35.25,55.76)33.74(29.04,44.76)0.001[^5]

Discussion {#S0004}
==========

POD is a prevalent clinical feature in LT patients postoperatively with a reported incidence of 10.0%-26.7%.[@CIT0005],[@CIT0007] The incidence of LT POD in this study was 26.4%, which was consistent with other studies. Previous studies have shown that alcohol abuse history, hepatic encephalopathy, APACHE II score ≥16, Child-pugh level C, MELD score ≥15, preoperative hemodialysis, and deceased liver donor are potentially related with the occurrence of LT POD.[@CIT0006],[@CIT0008] In this study, we found that hepatic encephalopathy, preoperative ammonia, MELD score, postoperative AST, and anhepatic period were the risk factors for POD via multivariate regression.

Currently, the pathogenesis of POD remains unclear as has been reported to be the result of multiple factors.[@CIT0009] The main physiopathologic mechanisms include blood-brain barrier injury, vascular endothelial cell injury, reduced cholinergic inhibitory receptor, neuroinflammation response, and disordered neurotransmitter.[@CIT0010] A systematic review on neuroimaging reported that white matter atrophy, edema, ischemic lesions, and inflammation in the frontal lobe, limbic system, parietal lobe and, temporal lobe were highly associated with POD.[@CIT0011] The cause for POD in LT patients postoperatively is complicated, which often suggests multiple factors.

Hepatic encephalopathy is reported to be one of the independent risk factors for LT POD.[@CIT0007],[@CIT0008] The physiopathologic mechanism of hepatic encephalopathy is complex and involves hyperammonemia, neuroinflammation reactions, neurotransmitter disorders, brain energy metabolism, and other factors.[@CIT0012] A neuroimaging study has demonstrated that during the development and progression of hepatic encephalopathy, patients will show interstitial edema,[@CIT0013] brain microstructural destruction,[@CIT0014] and white matter atrophy,[@CIT0015] all of which are related to attention deficit and cognitive dysfunction.[@CIT0016] The sites affected are located in the frontal lobe and basal ganglia[@CIT0017] and have similarities with the physiopathologic mechanism of POD, suggesting a role in high POD postoperative incidence in patients with hepatic encephalopathy.

Accumulation of ammonia is one of the main factors for the development and progression of hepatic encephalopathy. When hepatic encephalopathy happens, ammonia is not always increased, and patients with ammonia do not necessarily have hepatic encephalopathy.[@CIT0018] A recent study reported that ammonia had influences on the signaling pathway, gene expression and post-transcription protein modification,[@CIT0019],[@CIT0022] leading to damaged astrocytes, and manifesting as abnormal proliferation,[@CIT0023],[@CIT0024] the release of neurotransmitter[@CIT0022] or even apoptosis.[@CIT0023] As a part of the blood-brain barrier, astrocytes protect neuron from the toxicity of ammonia.[@CIT0025] Damage on this barrier will lead to brain edema.[@CIT0026] The sites of brain edema include the frontal lobe, temporal lobe, parietal lobe, and insular lobe,[@CIT0017],[@CIT0025] which may be related to the occurrence of delirium occurring in patients with hyperammonemia. In this study, we found that there was no correlation between ammonia and hepatic encephalopathy, and that ammonia was an independent risk factor for POD.

In anhepatic period, the whole liver of the recipient is resected. The portal vein, hepatic artery, and inferior vena cava above and below the liver are cut off, leading to hemodynamic changes, such as a decrease in venous return, cardiac output, and systemic circulation arterial pressure. These changes have an influence on cerebral blood perfusion and result in insufficient blood supply in the brain tissue. Meanwhile, metabolites are accumulated in the anhepatic period, resulting in metabolic disorders, such as acidosis, causing ischemia hypoxia injury and delirium.

ALT and AST are often used to assess the extent of damage in hepatocytes.[@CIT0027] In this study, AST was an independent risk factor for POD and AST increasing 1000u/l from the base level, the risk for the patient to suffer delirium increases by 1.33 times. Elevated postoperative AST and ALT possibly are related to the surgical operation and ischemia-reperfusion injury, suggesting the occurrence of delirium is closely related to donated liver injury and postoperative liver function recovery.

The MELD score is used to evaluate the severity of liver disease and acts as a general index for the distribution of liver and predicting mortality of patients waiting for transplant.[@CIT0028] In this study, a MELD score of ≥15 suggested an elevated risk of delirium.

According to related reports, drinking history is considered as one of the risk factors causing POD.[@CIT0008] However, in this study, alcoholic cirrhosis was not a risk factor for LT POD, possibly because there were few patients with alcoholic cirrhosis. The donor data in our center indicated that age of the donor, weight of donated liver, liver function, Na^+^ concentration, and coagulation function were not statistically different between the POD group and non-POD group.

In this study, the period of 3 days postoperatively has a higher incidence for delirium, during which period 78.6% of patients had developed POD. However, Lee et al,[@CIT0006] reported that 88% of LT POD had the onset on the first day, which differs from our report. The reason was that there were more hepatic encephalopathy patients among LT POD patients (50%, 21/42), and the anesthesia resuscitation time was relatively long, influencing initial delirium evaluation. Wang et al[@CIT0008] reported that the median duration of delirium onset was 5.5 days, which was consistent with our study. In this study, intubation time, ICU length of stay, and medical cost in the group were more than those in the non-POD group.

There is a little study in LT POD of prevention and treatment. Prevention with multicomponent nonpharmacological approaches remains important, such as The Hospital Elder Life Program (HELP).[@CIT0029] There is little evidence on the effects of nonpharmacological prevention. The pharmacological treatment of delirium in the ICU is still mostly based on clinical experience, as there is little high-quality evidence for its efficacy.[@CIT0030]

There are some limitations to our study. First, the study is retrospective, and the data are not comprehensive. Some potential information were not collected such as anaesthesia drug. Secondly, CAM-ICU has been widely applied in the clinic, and the experience from doctors and nurses influences the diagnosis of delirium, leading to bias.

Conclusion {#S0005}
==========

Hepatic encephalopathy, high preoperative ammonia, high MELD score, high postoperative AST, and long anhepatic period are the independent risk factors for LT POD occurrence. Enhancing the screening on LT POD patients, carefully monitoring patients with high MELD score or hepatic encephalopathy, and taking effective intervention in a timely manner will be helpful to reduce the occurrence of LT POD.
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[^1]: **Note:** Data are shown as mean ± SD or number (%).

[^2]: **Note:** Data are expressed as median \[Q25, Q75\] or number (%).

    **Abbreviations:** WBC, white blood cells; N%, percentage of neutrophils; HGB, hemoglobin; Na, sodium ion; Mg, magnesium ion; CREA, serum creatinine; PAB, prealbumin; ALB, albumin; TBIL, total bilirubin; DBIL, direct bilirubin; INR, international normalized ratio; FIB, plasma fibrinogen.

[^3]: **Note:** Data are expressed as median \[Q25, Q75\] or number (%).

    **Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; CREA, serum creatinine; PAB, prealbumin; ALB, albumin; TBIL, total bilirubin; DBIL, direct bilirubin; INR, international standardized ratio; FIB, plasma fibrinogen.

[^4]: **Note:** Data are expressed as median \[Q25, Q75\] or number (%).

    **Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; TBIL, total bilirubin; Na, sodium; PT, plasma prothrombin time; INR, international standardized ratio; FIB, plasma fibrinogen.

[^5]: **Note:** Data are expressed as median \[Q25, Q75\].
